blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2398771

EP2398771 - HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.06.2016
Database last updated on 24.07.2024
Most recent event   Tooltip17.08.2018Lapse of the patent in a contracting state
New state(s): BG		published on 19.09.2018  [2018/38]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim / DE
[2011/52]
Inventor(s)01 / BARTOLOZZI, Alessandra
Boehringer Ingelheim Pharmaceuticals Inc.
900 Ridgebury Road
P.O. Box 368
Ridgefield, Connecticut 06877 / US
02 / BERRY, Angela
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
P.O. Box 368
Ridgefield, Connecticut 06877 / US
03 / CIRILLO, Pier Francesco
Boehringer Ingelheim Pharmaceuticals Inc.
900 Ridgebury Road
P.O. Box 368
Ridgefield, Connecticut 06877 / US
04 / HICKEY, Eugene Richard
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
P.O. Box 368
Ridgefield, Connecticut 06877 / US
05 / RIETHER, Doris
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
P.O. Box 368
Ridgefield, Connecticut 06877 / US
06 / WU, Lifen
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
P.O. Box 368
Ridgefield, Connecticut 06877 / US
07 / ZINDELL, Renee M.
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
P.O. Box 368
Ridgefield, Connecticut 06877 / US
 [2011/52]
Representative(s)Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2012/40]
Former [2011/52]Hammann, Heinz
Boehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 173
55216 Ingelheim am Rhein / DE
Application number, filing date10704712.816.02.2010
WO2010US24270
Priority number, dateUS20090153333P18.02.2009         Original published format: US 153333 P
[2011/52]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010096371
Date:26.08.2010
Language:EN
[2010/34]
Type: A2 Application without search report 
No.:EP2398771
Date:28.12.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 26.08.2010 takes the place of the publication of the European patent application.
[2011/52]
Type: B1 Patent specification 
No.:EP2398771
Date:29.07.2015
Language:EN
[2015/31]
Search report(s)International search report - published on:EP11.11.2010
ClassificationIPC:C07D211/60, C07D401/12, C07D405/04, C07D413/12, C07D417/12, C07D417/14, A61K31/4545, A61P25/04
[2011/52]
CPC:
C07D413/12 (EP,US); A61P1/00 (EP); A61P1/02 (EP);
A61P1/04 (EP); A61P1/06 (EP); A61P1/16 (EP);
A61P11/00 (EP); A61P11/02 (EP); A61P11/04 (EP);
A61P13/12 (EP); A61P17/00 (EP); A61P17/02 (EP);
A61P19/00 (EP); A61P25/00 (EP); A61P25/02 (EP);
A61P25/04 (EP); A61P25/06 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P27/16 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P5/00 (EP); A61P7/00 (EP); A61P9/00 (EP);
A61P9/04 (EP); A61P9/10 (EP); C07D211/60 (EP,US);
C07D401/12 (EP,US); C07D405/04 (EP,US); C07D417/12 (EP,US);
C07D417/14 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2011/52]
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:DEN CB2-REZEPTOR MODULIERENDE HETEROCYCLISCHE VERBINDUNGEN[2011/52]
English:HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR[2011/52]
French:COMPOSÉS HÉTÉROCYCLIQUES QUI MODULENT LE RÉCEPTEUR CB2[2011/52]
Entry into regional phase19.09.2011National basic fee paid 
19.09.2011Designation fee(s) paid 
19.09.2011Examination fee paid 
Examination procedure19.09.2011Examination requested  [2011/52]
31.07.2012Despatch of a communication from the examining division (Time limit: M04)
08.10.2012Reply to a communication from the examining division
16.10.2013Despatch of a communication from the examining division (Time limit: M04)
12.02.2014Reply to a communication from the examining division
09.03.2015Communication of intention to grant the patent
15.06.2015Fee for grant paid
15.06.2015Fee for publishing/printing paid
15.06.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  31.07.2012
Opposition(s)02.05.2016No opposition filed within time limit [2016/27]
Fees paidRenewal fee
29.02.2012Renewal fee patent year 03
28.02.2013Renewal fee patent year 04
28.02.2014Renewal fee patent year 05
02.03.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.02.2010
AT29.07.2015
BE29.07.2015
BG29.07.2015
CY29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
MK29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
SM29.07.2015
TR29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
IE16.02.2016
LU16.02.2016
CH29.02.2016
LI29.02.2016
MT29.02.2016
[2018/38]
Former [2018/31]HU16.02.2010
AT29.07.2015
BE29.07.2015
CY29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
MK29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
SM29.07.2015
TR29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
IE16.02.2016
LU16.02.2016
CH29.02.2016
LI29.02.2016
MT29.02.2016
Former [2018/29]HU16.02.2010
AT29.07.2015
BE29.07.2015
CY29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
MK29.07.2015
MT29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
SM29.07.2015
TR29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
IE16.02.2016
LU16.02.2016
CH29.02.2016
LI29.02.2016
Former [2018/28]HU16.02.2010
AT29.07.2015
BE29.07.2015
CY29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
MK29.07.2015
MT29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
SM29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
IE16.02.2016
LU16.02.2016
CH29.02.2016
LI29.02.2016
Former [2017/47]AT29.07.2015
BE29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
MT29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
IE16.02.2016
LU16.02.2016
CH29.02.2016
LI29.02.2016
Former [2017/07]AT29.07.2015
BE29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
IE16.02.2016
LU16.02.2016
CH29.02.2016
LI29.02.2016
Former [2017/03]AT29.07.2015
BE29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
LU16.02.2016
CH29.02.2016
LI29.02.2016
Former [2016/46]AT29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
LU16.02.2016
BE29.02.2016
CH29.02.2016
LI29.02.2016
Former [2016/43]AT29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
LU16.02.2016
BE29.02.2016
Former [2016/42]AT29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
MC29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
BE29.02.2016
Former [2016/36]AT29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SI29.07.2015
SK29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
BE29.02.2016
Former [2016/24]AT29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SK29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
BE29.02.2016
Former [2016/23]AT29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
NL29.07.2015
PL29.07.2015
RO29.07.2015
SE29.07.2015
SK29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
Former [2016/22]AT29.07.2015
CZ29.07.2015
DK29.07.2015
EE29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
NL29.07.2015
PL29.07.2015
SE29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
Former [2016/21]AT29.07.2015
DK29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
IT29.07.2015
LT29.07.2015
LV29.07.2015
NL29.07.2015
PL29.07.2015
SE29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
Former [2016/20]AT29.07.2015
DK29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
LT29.07.2015
LV29.07.2015
NL29.07.2015
PL29.07.2015
SE29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
Former [2016/14]AT29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
LT29.07.2015
LV29.07.2015
NL29.07.2015
PL29.07.2015
SE29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
Former [2016/11]AT29.07.2015
ES29.07.2015
FI29.07.2015
HR29.07.2015
LT29.07.2015
LV29.07.2015
PL29.07.2015
SE29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
Former [2016/10]ES29.07.2015
FI29.07.2015
HR29.07.2015
LT29.07.2015
LV29.07.2015
PL29.07.2015
SE29.07.2015
NO29.10.2015
GR30.10.2015
IS29.11.2015
PT30.11.2015
Former [2016/09]FI29.07.2015
LT29.07.2015
LV29.07.2015
NO29.10.2015
GR30.10.2015
Former [2016/08]LT29.07.2015
NO29.10.2015
Former [2016/07]LT29.07.2015
Cited inInternational search[X]WO2005068448  (IONIX PHARMACEUTICALS LTD [GB], et al) [X] 7 * examples 73-77 *;
 [X]US6930115  (FUJII AKIHIRO [JP], et al) [X] 1-4,32,34 * compound 9 *;
 [X]WO2005044797  (ADDEX PHARMACEUTICALS SA [CH], et al) [X] 1,2,32 * example 62 *;
 [A]WO2008064054  (BOEHRINGER INGELHEIM INT [DE], et al) [A] 1-6,12,13,26-34 * the whole document *
 [X]  - CATALANO A ET AL, "Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR LNKD- DOI:10.1016/J.EJMECH.2008.01.023, vol. 43, no. 11, ISSN 0223-5234, (20081101), pages 2535 - 2540, (20080131), XP025571385 [X] 1,2,32 * compound 4b *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2008.01.023
 [X]  - IWAKUBO ET AL, "Design and synthesis of Rho kinase inhibitors (II)", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB LNKD- DOI:10.1016/J.BMC.2006.09.052, (20061115), vol. 15, no. 1, ISSN 0968-0896, pages 350 - 364, XP005764617 [X] 1,2,32 * compound 7b *

DOI:   http://dx.doi.org/10.1016/j.bmc.2006.09.052
 [X]  - KULKARNI ET AL, "Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB LNKD- DOI:10.1016/J.BMCL.2006.04.032, (20060701), vol. 16, no. 13, ISSN 0960-894X, pages 3371 - 3375, XP005461926 [X] 1-4,32 * compound 17b *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2006.04.032
by applicant   - ZIMMER ET AL., "Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB 1 receptor knockout mice", PROC NATL ACAD SCI U S A., (1999), vol. 96, doi:doi:10.1073/pnas.96.10.5780, pages 5780 - 5785, XP000982859

DOI:   http://dx.doi.org/10.1073/pnas.96.10.5780
    - KLEIN ET AL., "The cannabinoid system and immune system", J LEUKOC BIOL, (2003), vol. 74, doi:doi:10.1189/jlb.0303101, pages 486 - 496, XP001199700

DOI:   http://dx.doi.org/10.1189/jlb.0303101
    - BICKLET ET AL., "Immunomodulation by cannabinoid is absent in mice deficient for the cannabinoid CB2 receptor", EUR J PHARMACOL, (2000), vol. 396, pages 141 - 149, XP000991066
    - HANUS ET AL., "HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor", PROC NATL ACAD SCI U S A., (1999), vol. 96, doi:doi:10.1073/pnas.96.25.14228, pages 14228 - 14233, XP002638929

DOI:   http://dx.doi.org/10.1073/pnas.96.25.14228
    - UEDA ET AL., "Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice", EUR J PHARMACOL., (2005), vol. 520, doi:doi:10.1016/j.ejphar.2005.08.013, pages 164 - 171, XP005090462

DOI:   http://dx.doi.org/10.1016/j.ejphar.2005.08.013
    - SMITH ET AL., "The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models", EUR J PHARMACOL., (2001), vol. 432, pages 107 - 119
    - BAKER ET AL., "Cannabinoids control spasticity and tremor in a multiple sclerosis model", NATURE, (2000), vol. 404, doi:doi:10.1038/35003583, pages 84 - 87, XP000914618

DOI:   http://dx.doi.org/10.1038/35003583
    - AREVALO-MARTIN ET AL., "Therapeutic action of cannabinoids in a murine model of multiple sclerosis", J NEUROSCI., (2003), vol. 23, pages 2511 - 2516
    - MALAN ET AL., "CB2 cannabinoid receptor-mediated peripheral antinociception", PAIN, (2001), vol. 93, doi:doi:10.1016/S0304-3959(01)00321-9, pages 239 - 45, XP003015145

DOI:   http://dx.doi.org/10.1016/S0304-3959(01)00321-9
    - NACKLEY ET AL., "Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation", NEUROSCIENCE, (2003), vol. 119, pages 747 - 57
    - IBRAHIM ET AL., "Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS", PROC NATL ACAD SCI U S A., (2003), vol. 100, pages 10529 - 33
    - VAN SICKLE ET AL., "Identification and functional characterization of brainstem cannabinoid CB2 receptors", SCIENCE, (2005), vol. 310, pages 329 - 332
    - DUTTON,F. E., LEE, B. H., JOHNSON, S. S., COSCARELLI, E. M., LEE, P. H., J MED. CHEM., (2003), vol. 46, pages 2057 - 2073
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.